Sermorelin is not currently available in the United States as an FDA-approved commercial drug. The former brand Geref was FDA-approved for pediatric growth hormone deficiency-related uses, then voluntarily discontinued. Today, sermorelin is generally available as compounded sermorelin through a prescription; compounded medications are not FDA-approved finished products 1, 2.
Wondering if sermorelin is right for you? Take the 3-min clinical quiz.
See if you qualify →Is sermorelin FDA approved right now?
Sermorelin is not currently marketed as an FDA-approved commercial drug in the United States. The short answer is no current FDA-approved U.S. sermorelin product is available, even though a branded sermorelin product was approved in the past 1.
Short answer: no FDA-approved commercial sermorelin product is currently marketed in the U.S.
The older branded product was called Geref. It contained sermorelin acetate and was used in pediatric growth hormone deficiency-related care. That product is no longer commercially available 1.
What “FDA approved,” “discontinued,” and “compounded” mean for patients
- FDA approved means FDA reviewed a specific finished drug product for a specific use, dose form, labeling, manufacturing process, safety, and effectiveness.
- Discontinued means the branded commercial product is no longer marketed. Discontinuation does not always mean FDA found the drug unsafe or ineffective.
- Compounded means a pharmacy prepares a medication for an individual patient based on a prescription. Compounded drugs can be lawful, but they are not FDA-approved finished products 2.
Why is sermorelin no longer FDA approved?
Geref was discontinued by its manufacturer, so there is no current FDA-approved commercial sermorelin product on the U.S. market. That history matters, but it does not prove that today’s compounded sermorelin is safe, effective, or right for every patient 1, 2.
What happened to Geref
Geref was the former branded sermorelin acetate product. It was approved for pediatric growth hormone deficiency-related uses and later became unavailable as a marketed product 1.
Why discontinuation is different from an FDA safety ban
A discontinued listing is not the same thing as a public safety ban. Drugs may leave the market for business, manufacturing, demand, or other reasons. Patients should still avoid assuming that a discontinued drug’s past approval transfers to today’s compounded preparations 2.
Why this history does not prove current compounded products are safe or effective
FDA approval applies to a specific finished product. Compounded sermorelin is prepared outside the FDA new-drug approval process, so FDA has not reviewed each compounded product for safety, effectiveness, or quality before dispensing 2.
What is sermorelin and how does it work?
Sermorelin acetate is a synthetic version of part of growth hormone-releasing hormone, often shortened to GHRH. It works by signaling the pituitary gland to release growth hormone in pulses, rather than giving growth hormone directly 4.
Sermorelin acetate as a growth hormone-releasing hormone analog
Growth hormone-releasing hormone is made in the hypothalamus, a control center in the brain. Sermorelin is a GHRH analog, meaning it is designed to act at the same receptor pathway 4.
How sermorelin signals the pituitary to release growth hormone
The pituitary gland releases growth hormone after receiving GHRH signals. Growth hormone then travels through the blood and acts on tissues, including the liver 4.
How IGF-1 is used as a downstream marker
One downstream marker is insulin-like growth factor 1, or IGF-1. Clinicians may use IGF-1, along with symptoms, medical history, and other labs, to understand growth hormone-axis activity. IGF-1 alone does not diagnose every growth hormone problem 5.
How sermorelin differs from direct human growth hormone injections
Human growth hormone, or HGH, usually refers to recombinant human growth hormone, also called rhGH, which supplies growth hormone directly. Sermorelin works one step upstream by asking the pituitary to release the body’s own growth hormone signal 4, 6.
| Therapy | What it is | Main mechanism | FDA status discussed here | Key safety issues |
|---|---|---|---|---|
| Sermorelin acetate | GHRH analog | Signals the pituitary to release growth hormone | No current FDA-approved commercial sermorelin product marketed in the U.S. | Injection-site reactions, flushing, headache, nausea, dizziness; long-term adult wellness data are limited |
| Recombinant human growth hormone, or rhGH/HGH | Direct growth hormone replacement | Adds growth hormone directly | FDA-approved products exist for specific labeled indications, not general anti-aging | Fluid retention, joint pain, glucose effects, intracranial hypertension risk in some settings 6 |
| Macimorelin, sold as Macrilen | Oral diagnostic agent | Stimulates growth hormone release for testing | FDA-approved diagnostic test for adult growth hormone deficiency | QT prolongation risk and diagnostic-use precautions 3 |
Is compounded sermorelin legal to prescribe?
Compounded sermorelin via 503A pharmacy may be prescribed when a licensed clinician determines it is appropriate for an individual patient. The key safety line is licensed medical care and a state-licensed pharmacy, not no-prescription peptide sellers 2.
Prescription-only access through a licensed clinician
Sermorelin is not something patients should self-direct. A clinician should review goals, medical history, medications, contraindications, and labs before deciding whether sermorelin fits the care plan 5.
How 503A compounding pharmacies fit into care
A 503A compounding pharmacy can prepare a medication for an individual patient based on a valid prescription. FDA explains that compounded drugs can meet patient needs, but they are not FDA-approved products 2.
Risks of buying peptides without a prescription or from research-chemical sellers
No-prescription peptide websites may sell products labeled for “research” rather than patient care. That route skips the medical review, pharmacy controls, and follow-up that help reduce risk 2.
3-min quiz
Considering sermorelin with clinician guidance?
Chia offers sermorelin as injection, nasal spray, and tablets after an online health review by a licensed U.S. provider. A prescription requires a medical evaluation and is not guaranteed. Chia medications are compounded by state-licensed 503A pharmacies; compounded drugs are not FDA-approved.
What uses of sermorelin are approved, off-label, or investigational?
Adult anti-aging use is not an FDA-approved indication for sermorelin. The clearest approved-use history is the former pediatric Geref product; adult wellness goals remain off-label or investigational depending on the context 1, 5.
Previously approved pediatric uses for Geref
Geref was approved for pediatric growth hormone deficiency-related uses. That past approval does not mean compounded sermorelin is FDA-approved today 1, 2.
Adult growth hormone deficiency is an endocrinology question
Adult growth hormone deficiency should not be diagnosed from age, fatigue, body composition, or low energy alone. Endocrine Society guidance recommends formal evaluation, and macimorelin has been studied and approved as an oral diagnostic test for adult growth hormone deficiency 3, 5, 7.
Adult longevity, sleep, recovery, body composition, and anti-aging use
For adult wellness goals, the honest answer is that human evidence is limited. Some research on the growth hormone-releasing hormone pathway has looked at aging-related physiology, but large sermorelin-specific randomized trials in healthy adults have not established longer life, better recovery, or predictable body-composition results 4, 8.
How safe is sermorelin?
Sermorelin safety depends on the person, the product, the dose plan, and follow-up. Short-term use is often described as reasonably tolerated in clinical discussions, but long-term adult wellness safety data are limited 4, 8.
Common short-term side effects
Reported side effects can include injection-site reactions, flushing, headache, nausea, and dizziness. These are not the only possible side effects, and any swelling, rash, trouble breathing, or severe symptoms need urgent medical review 4, 6.
Serious but less common risks and allergic reactions
Growth hormone-axis therapies may affect fluid balance, joint symptoms, intracranial pressure in rare settings, and glucose handling. Direct rhGH labels also warn about glucose intolerance and other endocrine risks, which is one reason clinician monitoring matters for hormone-axis care 6.
Who may need extra caution or may not be eligible
People with active malignancy, pregnancy, breastfeeding, uncontrolled endocrine disease, diabetes concerns, or complex pituitary disease may need extra caution or specialist care. Adult growth hormone disorders can overlap with thyroid, adrenal, glucose, and pituitary conditions 5, 6.
What should not be mixed with sermorelin without clinician review?
Hormone-related medications should not be mixed or changed without a clinician reviewing the full picture. The main concern is overlapping endocrine effects, especially thyroid, steroid, glucose, and pituitary pathways 5, 6.
- Thyroid medications or untreated thyroid disease: thyroid status can affect growth hormone and IGF-1 interpretation 5.
- Glucocorticoids: steroid medicines can affect growth and hormone signaling, and should be reviewed before starting a growth hormone-axis therapy 5.
- Insulin or diabetes medications: growth hormone-axis therapies can affect glucose handling, so glucose monitoring may matter 6.
- Somatostatin-related medicines or endocrine therapies: somatostatin is part of the body’s growth hormone feedback system, so endocrine medication combinations need clinician review 5.
Is sermorelin safer than TRT or HGH?
Sermorelin, TRT, and HGH are different therapies for different problems. “Safer” depends on diagnosis, labs, goals, age, medical history, and whether the treatment is monitored 5, 6.
| Option | What it targets | What it is not | When specialist input may matter |
|---|---|---|---|
| Sermorelin | Growth hormone-releasing hormone pathway | Not direct HGH and not testosterone | Pituitary disease, abnormal IGF-1, diabetes risk, cancer history |
| TRT | Testosterone deficiency | Not a growth hormone treatment | Fertility goals, prostate concerns, heart risk, unclear diagnosis |
| HGH/rhGH | Growth hormone replacement for labeled conditions | Not general anti-aging care | Adult growth hormone deficiency testing, pituitary disease, glucose concerns |
An endocrinologist may be needed when there is known pituitary disease, very low or high IGF-1, multiple hormone abnormalities, possible adult growth hormone deficiency, or unclear lab results. Formal testing is often needed before labeling an adult with growth hormone deficiency 5, 7.
How does sermorelin at Chia work?
At Chia, sermorelin is available as sermorelin injection, nasal spray, and tablets, with plans currently starting at $179/mo for injection or nasal spray. Care starts with a 100% online health questionnaire, then a licensed U.S. provider reviews it and prescribes only when clinically appropriate.
If prescribed, sermorelin is compounded in the U.S. by state-licensed 503A pharmacies and shipped to your door. Dosing is provider-guided and adjusted over time, and patients can message their care team through the portal between visits.
| Chia sermorelin option | Form | Starting price listed in Chia catalog | Best fit may depend on |
|---|---|---|---|
| Sermorelin | Injection | From $179/mo | Comfort with injections, provider assessment, goals, and follow-up plan |
| Sermorelin | Nasal spray | From $179/mo | Preference for a non-injection route and clinician review |
| Sermorelin | Tablets | See product page for current pricing | Preference, eligibility, and provider-guided plan |
Chia also offers protocols that include sermorelin injection when clinically appropriate, including Foundation Longevity, which pairs sermorelin injection with NAD+ injection and glutathione injection, and Weight + Muscle, which combines sermorelin injection with a choice of GLP-1. These are still prescription pathways, not guaranteed approvals.
If you use an AI agent to help organize care, Chia can also be reached through DoctorMCP at mcp.chia.health for agent-assisted prescription access. The clinical standard is the same: a licensed provider must review your health information before any prescription decision.
What questions should you ask before considering sermorelin?
Before considering sermorelin, ask what problem is being evaluated and how success and safety will be tracked. A clear plan matters more than a peptide trend 5.
- 1What diagnosis or goal is being evaluated?
- 2Which labs may matter, such as IGF-1, thyroid markers, fasting glucose, or A1C?
- 3Which benefits are evidence-based, and which are still uncertain?
- 4What side effects should I watch for?
- 5How often will follow-up happen?
- 6Could my medications, thyroid status, glucose risk, pregnancy status, breastfeeding status, or cancer history affect eligibility?
3-min quiz
Start with a clinical review
If you want to discuss sermorelin with Chia, start with the online eligibility quiz. A licensed provider reviews your health information and decides whether treatment is appropriate. A prescription is not guaranteed, and compounded medications are not FDA-approved.
FAQ
No. Sermorelin is not currently available as an FDA-approved commercial drug in the U.S., but that is different from saying it is banned. Compounded sermorelin may be prescribed by a licensed clinician when appropriate.
The former branded product, Geref, was discontinued and is no longer marketed. A product being discontinued is not the same as an FDA safety ban. Still, today’s compounded sermorelin has not been FDA-approved as a finished product.
No. Compounded sermorelin is not an FDA-approved finished product. It may be prepared by a state-licensed compounding pharmacy when prescribed for an individual patient, but FDA does not review compounded drugs the same way it reviews approved drugs before dispensing.
Adults may be prescribed compounded sermorelin when a licensed clinician determines it is appropriate. Adult wellness, anti-aging, sleep, recovery, energy, and body-composition uses are not FDA-approved indications.
No. Sermorelin is not FDA approved for anti-aging, longevity, recovery, sleep, energy, or body-composition goals. Human evidence for these uses is limited, and no study has shown that sermorelin extends human lifespan.
No. Sermorelin is a GHRH analog that signals the pituitary gland to release growth hormone. HGH, or recombinant human growth hormone, supplies growth hormone directly.
Yes. Sermorelin should be used only with a prescription and clinician oversight. No-prescription research-chemical sellers do not provide the same medical review, pharmacy controls, or follow-up.
Athletes should be very cautious. Growth hormone secretagogues and growth hormone-related substances may be restricted or prohibited under anti-doping rules. Athletes should check current World Anti-Doping Agency rules and their sport’s policies before using any peptide.
References
- 1.U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, discontinued drug product listings for Geref (sermorelin acetate), accessed 2026.
- 2.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers, 2024.
- 3.U.S. Food and Drug Administration. Macrilen (macimorelin) prescribing information, 2023.
- 4.Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 2006.
- 5.Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 2011.
- 6.U.S. Food and Drug Administration. Genotropin (somatropin) prescribing information, 2020.
- 7.Garcia JM, Swerdloff R, Wang C, Kyle M, Kipnes M, Biller BMK, Cook D, Yuen KCJ, Bonert V, Dobs A, Molitch M, Merriam GR. Macimorelin as a diagnostic test for adult growth hormone deficiency. Journal of Clinical Endocrinology & Metabolism, 2018.
- 8.Merriam GR, Schwartz RS, Vitiello MV. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine, 2003.
- 9.World Anti-Doping Agency. The 2026 Prohibited List: International Standard, 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if sermorelin is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
